» Articles » PMID: 21151616

Roles and Targets of Class I and IIa Histone Deacetylases in Cardiac Hypertrophy

Overview
Specialty Biology
Date 2010 Dec 15
PMID 21151616
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiac hypertrophy occurs in association with heart diseases and ultimately results in cardiac dysfunction and heart failure. Histone deacetylases (HDACs) are post-translational modifying enzymes that can deacetylate histones and non-histone proteins. Research with HDAC inhibitors has provided evidence that the class I HDACs are pro-hypertrophic. Among the class I HDACs, HDAC2 is activated by hypertrophic stresses in association with the induction of heat shock protein 70. Activated HDAC2 triggers hypertrophy by inhibiting the signal cascades of either Krüppel like factor 4 (KLF4) or inositol polyphosphate-5-phosphatase f (Inpp5f). Thus, modulators of HDAC2 enzymes, such as selective HDAC inhibitors, are considered to be an important target for heart diseases, especially for preventing cardiac hypertrophy. In contrast, class IIa HDACs have been shown to repress cardiac hypertrophy by inhibiting cardiac-specific transcription factors such as myocyte enhancer factor 2 (MEF2), GATA4, and NFAT in the heart. Studies of class IIa HDACs have shown that the underlying mechanism is regulated by nucleo-cytoplasm shuttling in response to a variety of stress signals. In this review, we focus on the class I and IIa HDACs that play critical roles in mediating cardiac hypertrophy and discuss the non-histone targets of HDACs in heart disease.

Citing Articles

Zinc-Dependent Histone Deacetylases in Lung Endothelial Pathobiology.

Patil R, Maloney M, Lucas R, Fulton D, Patel V, Bagi Z Biomolecules. 2024; 14(2).

PMID: 38397377 PMC: 10886568. DOI: 10.3390/biom14020140.


Comparative Metabolomics in Single Ventricle Patients after Fontan Palliation: A Strong Case for a Targeted Metabolic Therapy.

Renaud D, Scholl-Burgi S, Karall D, Michel M Metabolites. 2023; 13(8).

PMID: 37623876 PMC: 10456471. DOI: 10.3390/metabo13080932.


The role of post-translational modifications in driving abnormal cardiovascular complications at high altitude.

Hou J, Wen X, Long P, Xiong S, Liu H, Cai L Front Cardiovasc Med. 2022; 9:886300.

PMID: 36186970 PMC: 9515308. DOI: 10.3389/fcvm.2022.886300.


Emerging epigenetic therapies of cardiac fibrosis and remodelling in heart failure: from basic mechanisms to early clinical development.

McKinsey T, Foo R, Anene-Nzelu C, Travers J, Vagnozzi R, Weber N Cardiovasc Res. 2022; 118(18):3482-3498.

PMID: 36004821 PMC: 10202443. DOI: 10.1093/cvr/cvac142.


Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.

Korfei M, Mahavadi P, Guenther A Cells. 2022; 11(10).

PMID: 35626663 PMC: 9139813. DOI: 10.3390/cells11101626.


References
1.
Cho Y, Eom G, Kee H, Kim H, Choi W, Nam K . Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circ J. 2010; 74(4):760-70. DOI: 10.1253/circj.cj-09-0580. View

2.
Gregoire S, Xiao L, Nie J, Zhang X, Xu M, Li J . Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol. 2006; 27(4):1280-95. PMC: 1800729. DOI: 10.1128/MCB.00882-06. View

3.
Liu Z, Li T, Liu Y, Jia Z, Li Y, Zhang C . WNT signaling promotes Nkx2.5 expression and early cardiomyogenesis via downregulation of Hdac1. Biochim Biophys Acta. 2008; 1793(2):300-11. DOI: 10.1016/j.bbamcr.2008.08.013. View

4.
Montgomery R, Potthoff M, Haberland M, Qi X, Matsuzaki S, Humphries K . Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest. 2008; 118(11):3588-97. PMC: 2556240. DOI: 10.1172/JCI35847. View

5.
Chang S, McKinsey T, Zhang C, Richardson J, Hill J, Olson E . Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol. 2004; 24(19):8467-76. PMC: 516756. DOI: 10.1128/MCB.24.19.8467-8476.2004. View